Disrupting CXCR2‐mediated trafficking of MDSCs improves the efficacy of anti‐PD1 treatment in pediatric sarcomas.[40] Thus, CXCR2 blockade was proposed to be a possible strategy for remodeling the microenvironment after the circulating osteosarcoma cells colonization. The gene discussed is CXCR2; the disease is osteosarcoma.